CD36/GP4 recombinant proteins and antibodies

CD36, also known as Platelet glycoprotein 4 (GP4) is a transmembrane glycoprotein widely expressed on various cell types, including macrophages, platelets, endothelial cells, and tumor cells. As an important receptor, CD36 plays a crucial role in lipid metabolism, immune responses, and immune evasion in the tumor microenvironment. By binding to multiple ligands such as oxidized low-density lipoprotein (oxLDL) and fatty acids, CD36 regulates immune responses and promotes inflammatory reactions. CD36 is highly expressed in several malignancies, including liver cancer, breast cancer, and lung cancer, with its expression level correlating with tumor metastasis, invasiveness, and patient prognosis.

In tumor immune evasion, CD36 mainly acts by modulating immune cells in the tumor microenvironment, promoting tumor growth and metastasis. By interacting with tumor-associated ligands, CD36 helps tumor cells escape immune surveillance. Research has also shown that CD36 promotes the polarization of tumor-associated macrophages (TAMs), which suppresses anti-tumor immune responses. Therefore, CD36 has emerged as a potential target in cancer immunotherapy.

Currently, ongoing drug development targeting CD36 primarily focuses on monoclonal antibodies and small molecule inhibitors. Monoclonal antibodies targeting CD36 can block its interaction with tumor ligands, thereby inhibiting tumor growth and metastasis. Additionally, small molecule inhibitors are being researched to target CD36, aiming to suppress tumor immune evasion and restore the body’s anti-tumor immune response. Several pharmaceutical companies have started to focus on the CD36 target and have invested heavily in the development of related therapies. Leading pharmaceutical companies such as Pfizer, Merck, and Gilead have made progress in the development of CD36-targeted drugs. Particularly in the context of tumor immune evasion, CD36-targeted therapies hold the potential to become a new breakthrough for treating tumor types resistant to traditional therapies. By combining with other immunotherapies or chemotherapy drugs, CD36-targeted therapies are expected to improve patient survival rates and quality of life.

To assist in the development of CD36 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CD36 targets. Products include active CD36 recombinant proteins, full-length CD36 proteins, CD36 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CD36 biotherapy, DIMA BIOTECH has also prepared a CD36 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD36 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.